Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres
NUCLEAR MEDICINE COMMUNICATIONS, vol.36, no.4, pp.340-349, 2015 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 36 Issue: 4
- Publication Date: 2015
- Doi Number: 10.1097/mnm.0000000000000257
- Journal Name: NUCLEAR MEDICINE COMMUNICATIONS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.340-349
- Keywords: survival, technetium-99m macroaggregated albumin, tumor response, yttrium-90, UNRESECTABLE HEPATOCELLULAR-CARCINOMA, Y-90 GLASS MICROSPHERES, RADIOEMBOLIZATION, RADIATION, THERAPY, DOSIMETRY, SECONDARY, TRIAL, Y-90-MICROSPHERES, BRACHYTHERAPY
- Akdeniz University Affiliated: Yes
Abstract
Objective Radioembolization with the yttrium-90 (Y-90) microspheres is being used increasingly more often in the treatment of patients with primary or metastatic liver cancer. Although technetium-99m macroaggregated albumin (Tc-99m MAA) scintigraphy performed following diagnostic angiography has an important role in predicting the effectiveness of treatment and in dose estimation, the number of studies using quantitative assessment of Tc-99m MAA scintigraphy is limited in this field. In the present study, the aim was to assess whether a tumor dose is required to obtain objective tumor response and to check whether this threshold value is predictive in terms of tumor response, survival, and liver toxicity by using Tc-99m MAA single-photon emission computed tomography (SPECT) images.